This newly opened laboratory at JWCI is focusing on adoptive immunotherapy using tumor-infiltrating lymphocytes (TILs). The goal is to develop individualized treatments using immune cells derived from a patient’s melanoma. Although adoptive T-cell immunotherapy can produce relatively high response rates, the complexity of expanding immune cells in culture and the time interval between tumor resection and treatment have limited its use. Using JWCI's experience in immunotherapy and cell culture, the lab will attempt not only to bring the therapy to our community, but also to develop simplified and more effective adoptive immunotherapy methodologies.
Melanoma Program at Saint John's Health Center ›